ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

PubWeight™: 1.08‹?› | Rank: Top 10%

🔗 View Article (PMC 3345278)

Published in Leukemia on August 26, 2011

Authors

D Bhojwani1, D Pei, J T Sandlund, S Jeha, R C Ribeiro, J E Rubnitz, S C Raimondi, S Shurtleff, M Onciu, C Cheng, E Coustan-Smith, W P Bowman, S C Howard, M L Metzger, H Inaba, W Leung, W E Evans, D Campana, M V Relling, C-H Pui

Author Affiliations

1: Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105, USA. deepa.bhojwani@stjude.org

Associated clinical trials:

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111

Articles citing this

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood (2012) 2.82

RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet (2014) 2.72

Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol (2015) 2.15

A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32

Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.19

Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. Haematologica (2012) 0.93

New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia. Haematologica (2016) 0.88

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer (2014) 0.84

Runx1 stabilizes the mammary epithelial cell phenotype and prevents epithelial to mesenchymal transition. Oncotarget (2017) 0.82

Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing. Cancer Med (2015) 0.80

Leukaemia 'firsts' in cancer research and treatment. Nat Rev Cancer (2016) 0.79

Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor. Mol Cytogenet (2015) 0.78

Targeted Theranostic Approach for Glioma Using Dendrimer-Based Curcumin Nanoparticle. J Nanomed Nanotechnol (2016) 0.76

RUNX1 truncation resulting from a cryptic and novel t(6;21)(q25;q22) chromosome translocation in acute myeloid leukemia: A case report. Oncol Rep (2016) 0.75

Prognostification of ALL by Cytogenetics. Indian J Hematol Blood Transfus (2014) 0.75

Outcome and Prognostic Factors for ETV6/RUNX1 Positive Pediatric Acute Lymphoblastic Leukemia Treated at a Single Institution in Korea. Cancer Res Treat (2016) 0.75

Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean J Pediatr (2017) 0.75

Pediatric haematopoiesis and related malignancies. Oncol Lett (2017) 0.75

Articles cited by this

Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep (1966) 48.83

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Prenatal origin of acute lymphoblastic leukaemia in children. Lancet (1999) 4.21

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood (2010) 4.17

Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol (2010) 3.02

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood (2003) 2.65

Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol (2008) 2.29

Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood (2002) 1.74

Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 1.39

The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood (1996) 1.30

Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood (2006) 1.28

TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity. Blood (2004) 1.18

Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Study Group. Blood (1997) 1.16

The TEL-AML1 leukemia fusion gene dysregulates the TGF-beta pathway in early B lineage progenitor cells. J Clin Invest (2009) 1.15

TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood (2000) 1.10

TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol (1997) 1.04

L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia (1995) 1.00

Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol (2008) 0.99

Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol (2008) 0.93

The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia (2001) 0.88

Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood (2004) 0.84

Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells. Leuk Lymphoma (2010) 0.82

Chemosensitivity of TEL-AML1 fusion transcript positive acute lymphoblastic leukemia cells. Leuk Lymphoma (2001) 0.81

Novel cryptic, complex rearrangements involving ETV6-CBFA2 (TEL-AML1) genes identified by fluorescence in situ hybridization in pediatric patients with acute lymphoblastic leukemia. Genes Chromosomes Cancer (2001) 0.80

Articles by these authors

Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25

Calcium regulation of growth and differentiation of mouse epidermal cells in culture. Cell (1980) 8.10

Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet (2004) 7.33

The complete DNA sequence of Autographa californica nuclear polyhedrosis virus. Virology (1994) 5.93

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44

TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia (2003) 4.17

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13

High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet (1999) 3.63

Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59

Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia (2004) 3.59

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58

The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron (2001) 3.56

High-throughput genotyping with single nucleotide polymorphisms. Genome Res (2001) 3.55

Undergraduate research. Genomics Education Partnership. Science (2008) 3.45

Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol (1993) 3.41

Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med (1998) 3.41

Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (1995) 3.38

The mammalian sodium channel BNC1 is required for normal touch sensation. Nature (2000) 3.30

Foreign-body perforation of the intestinal tract. Report of 12 cases and review of the literature. Arch Surg (1970) 3.26

Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26

Acute lymphoblastic leukemia. N Engl J Med (1998) 3.15

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet (1998) 3.07

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood (2000) 2.92

Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ (2000) 2.91

Tretinoin toxicity in children with acute promyelocytic leukaemia. Lancet (1993) 2.85

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72

Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol (2004) 2.63

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59

TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 2.54

Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48

Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults. Proc Natl Acad Sci U S A (1992) 2.41

The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39

Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38

Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther (2011) 2.33

Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science (1998) 2.31

Identification of a major keratinocyte cell envelope protein, loricrin. Cell (1990) 2.25

Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24

Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science (1992) 2.19

Myeloid neoplasia in children treated for solid tumours. Lancet (1990) 2.18

The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18

Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood (1999) 2.18

Heat flow and distribution during induction of general anesthesia. Anesthesiology (1995) 2.12

A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12

Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med (1996) 2.10

Cyclin partners determine Pho85 protein kinase substrate specificity in vitro and in vivo: control of glycogen biosynthesis by Pcl8 and Pcl10. Mol Cell Biol (1998) 2.04

Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther (2013) 1.99

Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica (2006) 1.96

Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94

Lipoprotein analysis in the evaluation of chest pain in the emergency department. Mayo Clin Proc (1991) 1.92

Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91

Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia (2004) 1.87